Revealing novel mode of action for osteoporosis drug

29 agosto 2014

Raloxifene is a US Food and Drug Administration-approved treatment for decreasing fracture risk in osteoporosis. While raloxifene is as effective at reducing fracture risk as other current treatments, this works only partially by suppressing bone loss. X-ray studies revealed an additional mechanism underlying raloxifene action, providing an explanation for how this drug can achieve equivalent clinical benefit.